Trials / Recruiting
RecruitingNCT02932150
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAF | Administered orally once daily |
| DRUG | Placebo | Administered orally once daily |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2026-09-01
- Completion
- 2029-10-01
- First posted
- 2016-10-13
- Last updated
- 2026-04-03
Locations
62 sites across 11 countries: United States, Belgium, Canada, Hong Kong, India, Italy, New Zealand, Romania, Russia, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02932150. Inclusion in this directory is not an endorsement.